Alnylam Pharmaceuticals' stock recently hit a new milestone, closing at an all-time high of $303.25 on May 30, 2025. This closing price marks a 3.53% increase compared to its prior session, highlighting continued investor enthusiasm for the biotechnology company.
Contributing to this upward momentum, Alnylam's previous record was $300.55, set on October 16, 2024. The stock's 52-week range further emphasizes its upward journey, leaping from a low of $144.73 to a fresh high of $304.39. Institutional interest also plays a notable role in this performance, with T. Rowe Price Investment Management significantly upping its stake by 39.7%, now holding shares worth around $1.03 billion.
In a related development, major financial institutions are keeping a watchful eye on Alnylam's stock. In March 2025, JPMorgan Chase & Co. adjusted its target price from $272.00 to $280.00 while maintaining a neutral outlook. These moves suggest that while the market sees potential in Alnylam, it remains cautiously measured in its forecast, as noted by Marketbeat.